Abstract
Major finding: ROS1 chromosomal rearrangements define a molecular subtype of NSCLC.
Impact: ROS1 rearrangements tend to occur in younger, non-smoking NSCLC patients.
Clinical relevance: ROS1-positive NSCLC patients may benefit from crizotinib therapy.
This content is only available via PDF.
©2012 American Association for Cancer Research.
2012
RSS Feeds